09/2020: Case study with Evidentic
and UGA Biopharma collaborated for a case study which was recently published on
the website of Evidentic, “Aliquots: A New Solution to the Batch Variability
To read the
case study, which was developed with the help of our Team Leader Analytics/DSP Dr.
Stephan Schultz, please click here.
reference drugs in small quantities as ‘drug aliquots’, from EU licensed
medicines. Its portfolio includes mAb drugs like Adalimumab, Bevacizumab,
Ipilimumab, Pembrolizumab, and Trastuzumab, among others.
Biopharma offers Cell line development services, specializing in the
development of stable expressing CHO cell lines and cell media for the
production of biologics and biosimilars for biopharmaceutical companies.